Drug Profile
Chronic myeloid leukaemia vaccine
Alternative Names: Ablvax; Chronic myelogenous leukaemia vaccine; CMLVAX 100; CMLVAX 500; Multivalent BCR-ABL oncogene product fusion peptide vaccine; VAX 100Latest Information Update: 23 Jun 2015
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Breakthrough Therapeutics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic myeloid leukaemia
Most Recent Events
- 12 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the adverse events and Cancer therapeutic trials section ,
- 04 Mar 2005 The vaccine has been licensed to Breakthrough Therapeutics
- 04 Mar 2005 Data from a media release have been added to the Cancer therapeutic trials section